A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa

drug protocol number

M20-465

drug sponsor

AbbVie Biopharmaceuticals GmbH ScientificOffice

drug study

Lutikizumab

drug trial site

King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Jeddah)

drug status

Ongoing

drug phase